Sign Up to Support SSDP and Science at Historic Public Hearing on DOI and DOC
SSDP is leading the fight to keep psychedelic research legal!
The DEA wants to add two important research chemicals—2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC)—to Schedule I of the Controlled Substances Act, despite decades of safe usage in labs and no history of abuse. DOI and DOC’s current status as unscheduled compounds has made them de facto tools for researchers studying serotonin receptors.
SSDP will continue our multi-year effort to prevent the Drug Enforcement Administration (DEA) from effectively blocking crucial medical research, in an unprecedented ten-day long public hearing taking place November 12 through 25 at the DEA Headquarters in Arlington, Virginia.
The future of psychedelics rests in our hands.
Join the fight to keep DOI and DOC legal!
